Central and Peripheral Molecular Targets for Antiobesity Pharmacotherapy
Authors:
- 5 May 2010
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 87 (6) , 652-662
Abstract
Obesity has emerged as one of the principal worldwide health concerns of the modern era, and there exists a tremendous unmet clinical need for safe and effective therapies to combat this global pandemic. The prevalence of obesity and its associated comorbidities, including cardiovascular and metabolic diseases, has focused the attention of those in drug discovery and development on generating effective modalities for the treatment and prevention of obesity. Early efforts in the field of obesity pharmacotherapy centered on the development of agents with indeterminate mechanisms of action. This led to treatment paradigms characterized by significant off-target effects. In the past two decades, new insights have been made into the physiologic regulation of energy balance and the subordinate central and peripheral circuits coordinating appetite, metabolism, and lipogenesis. These studies have revealed previously unrecognized molecular targets for controlling appetite and managing weight from which has emerged a new wave of targeted pharmacotherapies to prevent and control obesity.Keywords
This publication has 35 references indexed in Scilit:
- New central targets for the treatment of obesityBritish Journal of Clinical Pharmacology, 2009
- Regulatory challenges for new drugs to treat obesity and comorbid metabolic disordersBritish Journal of Clinical Pharmacology, 2009
- Gut Peptides: Targets for Antiobesity Drug Development?Endocrinology, 2009
- Endoplasmic Reticulum Stress Plays a Central Role in Development of Leptin ResistanceCell Metabolism, 2009
- Inhibition of ghrelin O -acyltransferase (GOAT) by octanoylated pentapeptidesProceedings of the National Academy of Sciences, 2008
- Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studiesProceedings of the National Academy of Sciences, 2008
- Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adultsCell Metabolism, 2006
- Vaccination against weight gainProceedings of the National Academy of Sciences, 2006
- Valvular Heart Disease Associated with Fenfluramine–PhentermineNew England Journal of Medicine, 1997
- Anorectic and behavioural effects of bupropionGeneral Pharmacology: The Vascular System, 1988